Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
33 hedge funds and large institutions have $44.8M invested in Trillium Therapeutics Inc. in 2015 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 9 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 34 → 33 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
36% less capital invested
Capital invested by funds: $69.9M → $44.8M (-$25.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$2.95M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$2.36M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$1.16M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$919K |
| 5 |
Millennium Management
New York
|
+$416K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.57M |
| 2 |
SIM
Spark Investment Management
New York
|
-$785K |
| 3 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$478K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$436K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$425K |
TRIL Hedge Fund Activity: Q3 2015 in Review
33 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2015, worth a combined $44.8M — down 36% from $69.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TRIL and 8 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 9 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $2.95M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $2.57M sold.
- 33 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2015, down from 34 in Q2 2015.
- Funds reported $44.8M of Trillium Therapeutics Inc. stock for Q3 2015, down 36% quarter-over-quarter.
- 8 funds opened new Trillium Therapeutics Inc. positions in Q3 2015 and 9 closed out, a net change of -1 holder.
- The largest Trillium Therapeutics Inc. buyer in Q3 2015 was Avoro Capital Advisors, an estimated $2.95M added.
- The largest Trillium Therapeutics Inc. seller in Q3 2015 was Bogle Investment Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q3 2015.